期刊文献+

苹果酸舒尼替尼抑制膀胱癌T24细胞系的体外增殖 被引量:4

Sunitinb Inhibits the proliferation of human bladder cancer line T24 in vitro
下载PDF
导出
摘要 目的探讨苹果酸舒尼替尼对人膀胱癌T24细胞系体外增殖的影响。方法取人膀胱癌T24细胞系悬液,分别加入浓度为0.625、1.25、2.5、5、10和20μmol/L的苹果酸舒尼替尼,分别于24、48及72 h进行处理,用细胞毒抑制实验(MTT法)检测药物对其生长的影响。结果苹果酸舒尼替尼可浓度依赖地抑制人膀胱癌细胞系T24细胞增殖,当药物浓度>5μmol/L时,苹果酸舒尼替尼与顺铂比较,对T24细胞系具有更强的抑制作用(P<0.05)。这种抑制作用随着药物培育时间延长(24、48、72 h)而增强,表现为IC50值显著降低,但其抑制能力与顺铂比较无显著差别。结论苹果酸舒尼替尼可呈浓度和时间依赖地抑制膀胱癌T24细胞系增殖。 Objective The study is aimed at determining inhibition effect on human bladder cancer line T24 by sunitinb in vitro.Methods T24 bladder cells line were treated by 0.625,1.25,2.5,5,10 and 20 μmol/L sunibinib in 24,48 and 72 h.The cytotoxic activity was analyzed by MTT.Results Sunitinib inhibited T24 cell proliferation in dose-dependent manner.When the plasma drug concentration exceeded up to 5 μmol/L,the inhibitory rate of Sunibinib was more than Cisplatin(P〈0.05).Inhibitory rate of Sunibinib increased with the extension of incubation time,which showed no significant difference to Cisplatin.Conclusion Sunitinib inhibited bladder cell line T24 proliferation in dose-dependent and time dependent manner.
出处 《基础医学与临床》 CSCD 北大核心 2011年第9期988-990,共3页 Basic and Clinical Medicine
基金 北京市自然科学基金(7102128) 北京协和医院青年科研基金(2010)
关键词 膀胱肿瘤 舒尼替尼 T24细胞系 bladder cancer sunitinib T24 cell line
  • 相关文献

参考文献6

  • 1Dr. F. Dorp,C. B?rgermann,A. Rose,M. Becker,H. Rübben.Targeted-Therapie des metastasierten Urothelkarzinoms[J]. Der Urologe . 2008 (10)
  • 2Ono M,Hirata A,Kometani T.Sensitivity to gefitinib (Ires-sa,ZD1839)in non-small cell lung cancer cell lines corre-lates with dependence on the epidermal growth factor (EGF)receptor/extracellular signal-regulated kinase 1/2and EGF receptor/Akt pathway for proliferation. MolCancer Ther . 2004
  • 3Silay MS,Miroglu C.Sunitinib malate and sorafenib maybe beneficial at the treatment of advanced bladder cancerdue to their anti-angiogenic effects. Medical Hypotheses . 2007
  • 4Beekman KW,Bradley D,Hussain M.New molecular tar-gets and novel agents in the treatment of advanced urothelialcancer. Seminars in Oncology . 2007
  • 5Landis SH,Murray T,Bolden S,et al.Cancer statistics, 1999. CA A Cancer Journal for Clinicians . 1999
  • 6Froehner M,Hakenberg OW,Wirth MP.Molecular therapy in urologic oncology. Urologia Internationalis . 2007

同被引文献43

  • 1张珊文,肖绍文,刘长清,孙艳,苏星,李东明,徐刚,蔡勇,朱广迎,徐博,吕有勇.重组人p53腺病毒注射液联合放射线治疗头颈鳞癌的Ⅱ期临床试验[J].中华医学杂志,2003,83(23):2023-2028. 被引量:69
  • 2陈传本,潘建基,徐鹭英.重组人p53腺病毒注射液结合放射治疗鼻咽癌Ⅱ期临床试验观察[J].中华医学杂志,2003,83(23):2033-2035. 被引量:52
  • 3YANG Tu-bao,ZENG Fu-hua,SUN Zhen-qiu.Prognostic factors for primary superficial transitional cell carcinoma of the bladder:a retrospective cohort study[J].Chinese Medical Journal,2006(21):1821-1828. 被引量:3
  • 4Jacobs BL,Lee CT,Montie JE.Bladder Cancer in 2010:How Far have We Come?[J].CA Cancer J Clin,2010,60:244-272.
  • 5Gallagher DJ,Milowsky MI,Gerst SR,et al.Phase II studyof sunitinib in patients with metastatic urothelial cancer[J].J Clin Oncol,2010,28:1373-1379.
  • 6Mitra,AP,Cote,RJ.Molecular pathogenesis and diagnos-tics of bladder cancer[J].Annu Rev Pathol,2009,4:251-285.
  • 7Bourguignon LY,Gilad E,Rothman K,et al.Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERKsignaling,leading to actin binding,Elk-1/estrogen receptortranscriptional activation,and ovarian cancer progression[J].J Biol Chem,2005,280:11961-11972.
  • 8Adamia S,Maxwell CA,Pilarski LM.Hyaluronan and hya-luronans synthases:Potential therapeutic targets in cancer[J].Curr Drug Targets Cardiovase Haematol Disord,2005,5:3-14.
  • 9Nagano O,Saya H.Mechanismand biological significance ofCD44 cleavage[J].Cancer Sci,2004,95:930-935.
  • 10Weber GF,Bronson RT,Ilagan J,et al.Absence of theCD44 gene prevents sarcoma metastasis[J].Cancer Res,2002,62:2281-2286.

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部